Clinical Trials Sponsored by Baylor Research Institute

Total 17545 results

Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Treatment of Venous Thromboembolism in Cancer Patients

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China (XAPEC)

Pulmonary Embolism

China
Bayer
Janssen Research & Development, LLC

Completed

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes (RIVA-DM)

Atrial Fibrillation

United States
Charité Research Organisation GmbH
Bayer

Completed

Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat (NIC-002)

Healthy Volunteers

Germany
Bayer
Janssen Research & Development, LLC

Completed

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Venous Thrombosis | Atrial Fibrillation | Acute Coronary Syndrome | Pulmonary Embolism

United Kingdom
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon (ReLoaDeD)

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation (XaMINA)

Atrial Fibrillation

Korea, Republic of, Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

Nonvalvular Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

Clinical Pharmacology

Japan
Bayer
Janssen Research & Development, LLC

Terminated

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (GALILEO)

Transcatheter Aortic Valve Replacement

Belgium, France, Germany, Spain, United States, Switzerland, Canada, Austria, United Kingdom, Korea, Republic of, Denmark, Italy, Netherlands, Poland, Czechia, Sweden, Norway
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Janssen Research & Development, LLC
Bayer

Completed

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER)

Heart Failure | Rheumatic Diseases | Respiratory Insufficiency | Infectious Diseases | Stroke Acute

United States, Poland, Ukraine, United Kingdom, Germany, Spain, Argentina, Belarus, Colombia, Israel, Mexico, Portugal, Bulgaria, Romania, Serbia, South Africa, Turkey, Canada, Australia, Netherlands, Denmark, Greece, Peru, Brazil, Russian... and more
Janssen Research & Development, LLC
Bayer

Completed

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Neoplasms

United States, France, United Kingdom, Germany, Belgium, Bulgaria, Canada, Brazil, Russian Federation, Czechia
Bayer
Janssen Research & Development, LLC

Completed

Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden

Atrial Fibrillation

Sweden
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study (X-PRESS)

Atrial Fibrillation

Taiwan
Bayer
Janssen Research & Development, LLC

Completed

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Atrial Fibrillation

Spain
Carolina Research Professionals, LLC
Bayer

Completed

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis (eRADicAte)

Prostate Cancer

United States
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEINJunior)

Venous Thrombosis

France, United States, Switzerland, Netherlands, Canada, Germany, Austria, Australia, Israel, Italy
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers

Healthy

Belgium
Janssen Research & Development, LLC
Bayer

Completed

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Healthy

Belgium
Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Regulatory Post-Marketing Surveillance

Venous Thromboembolism

Korea, Republic of
Bayer
Janssen Research & Development, LLC

Completed

Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication (SATORI)

Venous Thrombosis

France
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Venous Thromboembolism

Switzerland, China, Slovakia, France, Germany, Hungary, Korea, Republic of, Singapore, South Africa, Spain, Sweden, Philippines, Australia, Austria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Latvia, Lebanon, Lithuania, Macedonia... and more
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
Janssen Research & Development, LLC
Bayer

Completed

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Healthy | Renal Insufficiency

United States
Bayer
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (XARIN)

Non-valvular Atrial Fibrillation (NVAF)

India
Bayer
Janssen Research & Development, LLC

Completed

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer (COSIMO)

Venous Thrombosis and Pulmonary Embolism

Italy, Germany, United Kingdom, France, Belgium, Canada, Netherlands, Spain, Denmark, Australia
Bayer
Janssen Research & Development, LLC

Completed

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban) (FARAONIC)

Heart Failure

Spain
Bayer
Janssen Research & Development, LLC

Completed

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE) (JPMS-XAR-VTE)

Venous Thromboembolism

Japan
Bayer
Janssen Research & Development, LLC

Completed

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism) (H2H-OSCAR-US)

Cancer | Venous Thromboembolism | Treatment of Venous Thromboembolism in Cancer Patients

Germany
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

Coronary Artery Disease | Cardiovascular Disease

Belgium, Netherlands
Janssen Research & Development, LLC
Bayer

Completed

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure (UNIVERSE)

Thrombosis

United States, Spain, Argentina, Malaysia, Japan, Belgium, Canada, Netherlands, Brazil, Mexico
Charité Research Organisation GmbH
Bayer

Terminated

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat (NICCAM)

Covid19

Germany
Bayer
Janssen Research & Development, LLC

Completed

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA LEA)

Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)

Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
Janssen Research & Development, LLC
Bayer

Completed

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)

Coronary Artery Disease | Heart Failure

United States, France, Poland, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Mexico, Portugal, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Japan, Canada, Netherlands, Den... and more
Bayer
Janssen Research & Development, LLC

Completed

Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies (SULTAN)

Atrial Fibrillation

Spain
Canadian Collaborative Research Network
Bayer

Completed

Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF)

Cardiovascular Diseases

Canada
Bayer
Janssen Research & Development, LLC

Completed

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (XANTUS-EL)

Atrial Fibrillation

Colombia, Kazakhstan, Mexico, Russian Federation, Argentina, Azerbaijan, Bahrain, Chile, Egypt, Georgia, Jordan, Kenya, Lebanon, Saudi Arabia, United Arab Emirates, Uruguay, Venezuela
Bayer
Janssen Research & Development, LLC

Withdrawn

Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm (VeriXAPPORT)

Atrial Fibrillation | Venous Thromboembolism | Pulmonary Embolism
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA (RIVA-F)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (NEURO-XAR)

Stroke | Embolism

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (SOPRANO)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Russian Federation
Bayer
Janssen Research & Development, LLC

Completed

Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (XALIA)

Venous Thrombosis | Deep Vein Thrombosis

Switzerland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Moldova, Republic of, Slovenia, Ukraine, United Kingdom, Israel, Portugal, Belgium, Denmark, Greece, Netherlands, Canada, Norway
Bayer
Janssen Research & Development, LLC

Completed

Dose-confirmatory Bridging Study in Total Hip Replacement

Venous Thromboembolism

Japan
Canadian Urology Research Consortium
Bayer

Withdrawn

Radium 223 Following Intermittent ADT (RAND)

Prostate Cancer

Canada
Bayer
Janssen Research & Development, LLC

Completed

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter (X-TRA)

Atrial Fibrillation

France, Germany, Turkey, Russian Federation, Bulgaria, Ukraine, Poland

Clinical Trials Sponsored by Baylor Research Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations